Eisai aims to improve business efficiency and productivity and promptly maximize contribution to patients by leveraging global partnerships.
-
*Details of the agreements below are as of the end of March 2020.
Strategic Collaboration
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
|
Biogen (U.S.A.)
|
March 4, 2014
|
1. Acquisition of option rights for co-development/co-promotion of the Eisai-developed anti-amyloid beta (Aβ) protofibril antibody BAN2401 and the BACE inhibitor E2609 (generic name: elenbecestat)*1, and co-development/co-promotion of a Biogen-developed anti-tau antibody
2. Co-development/co-promotion of the Biogen-developed anti-Aβ antibody BIIB037 (generic name: aducanumab)
|
| U.S. Merck |
March 7, 2018
|
Co-development/co-promotion of Eisai’s anticancer agent Lenvima as monotherapy and in combination with U.S. Merck’s anti-PD-1 antibody Keytruda for a number of cancer types |
| Nichi-Iko Pharmaceutical Co., Ltd.*2 |
March 28, 2018
|
1. Collaboration in building the Company’s Total Inclusive Ecosystem
2. Partnership in the active pharmaceutical ingredient business
|
*1 In September 2019, Biogen and Eisai discontinued Phase III testing to verify the efficacy and safety of E2609 (generic name: elenbecestat).
*2 In April 2019, the Company completed the gradual transfer of shares of Elmed Eisai, Co., Ltd. stock.
Licensing
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
|
Fujifilm Corporation
Toyama Chemical Co., Ltd.
|
September 30, 1998
|
Joint development of and marketing alliance for the rheumatoid arthritis agent Careram (generic name: iguratimod) |
|
AbbVie Deutschland GmbH & Co. KG (Germany)
|
June 16, 1999 | Development and sale of the fully human anti-TNF-α monoclonal antibody Humira (generic name: adalimumab) in Japan, Taiwan*3, and South Korea |
|
Novartis AG (Switzerland)
|
February 6, 2004 | License for worldwide development, manufacturing, and sale of the antiepileptic agent Inovelon (generic name: rufinamide) |
|
Sunovion Pharmaceuticals Inc. (U.S.A.)
|
July 26, 2007 | Exclusive license for the development and marketing of the insomnia treatment Lunesta (generic name: eszopiclone) in Japan |
|
BioArctic (Sweden)
|
December 3, 2007 | Exclusive license for worldwide research and development, manufacturing, and sale of the anti-Aβ protofibrils antibody BAN2401 for the treatment of Alzheimer’s disease |
|
Pfizer Inc. (U.S.A.)
|
September 24, 2009 | Co-promotion agreement in Japan for the pain treatment agent Lyrica (generic name: pregabalin) |
| Prism BioLab Co., Ltd. |
April 1, 2011
|
Exclusive license for worldwide development, manufacturing, and sale of the anticancer agent E7386 |
|
University of London (U.K.)
|
October 16, 2015 | Collaborative research and co-development of the anti-tau antibody E2814 |
|
Meiji Seika Pharma Co., Ltd.
|
March 31, 2017 | Licenses related to exclusive sales rights in Japan and exclusive development and sales rights in 7 Asian countries for the anti-Parkinson’s disease agent Equfina (generic name: safinamide) |
|
Harvard University (U.S.A.)
|
June 15, 2018 |
Exclusive license for worldwide development, manufacturing, and sale of anticancer agent E7130
|
|
Gilead Sciences, Inc.
|
December 24, 2019
|
Marketing alliance contract for the selective Janus kinase 1 inhibitor filgotinib (generic name) in Japan |
| Minophagen Pharmaceutical Co., Ltd. |
February 29, 2016
|
Exclusive development and sales rights of the liver disease/ allergic disease agents Stronger Neo-Minophagen C (glycyrrhizic acid, compound formulation) and Glycyron Tablets (glycyrrhizic acid, compound tablet) in Japan and other Euro-Asian countries where the products have not yet been sold, and exclusive first negotiation rights in China and other Euro-Asian countries where the products are already sold |
Joint Venture
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
| Ajinomoto Co., Inc. | October 15, 2015 | Integration agreement concerning the splitting off of a portion of Eisai’s business and its subsequent succession by Ajinomoto Pharmaceuticals Co., Ltd. via an absorption-type split, etc. |
Other Contracts Important for Business
*You can scroll to the left or right here
| Party to contract | Date of conclusion | Contract content |
|---|---|---|
|
World Health Organization (WHO) (Switzerland)
|
January 30, 2012 | Provision of DEC (generic name: diethylcarbamazine) tablets to the WHO free of charge to support its program to eliminate lymphatic filariasis |